Lttl review
Three discounts, one headline
$149 a month, marked down from $179, with a $119 first month and a term ladder reaching $109 — three reductions applied to a single figure.
Our verdict
Lttl sells a low-dose line at low-dose prices and hangs three discount devices on the same headline: a struck-through $179, a $119 first month, and a four-rung term ladder down to $109. Stacked together they make the offer difficult to read and the standing rate easy to lose. The dosing approach is stated plainly, which counts for more than any of the three, because a reduced protocol is a different product rather than a cheaper version of the same one.
Disclosure: GLP Loss is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
At a glance
- Category
- GLP-1 pricing
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection · Oral
- Dose pricing
- Flat across doses
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
- Pharmacy
- Not named
- Updated
- September 2026
What it is
A telehealth seller of a low-dose injectable semaglutide, an oral semaglutide, and a low-dose GLP-1 and GIP product in the tirzepatide class, each sold on the same four term lengths.
How it works
Prescription-gated telehealth built around reduced doses and marketed for tolerability. Every product is sold month to month or on quarterly, six-month or annual terms, with a discounted first month offered against the month-to-month rate.
Pricing transparency
Injectable semaglutide: $149 month to month against a struck-through $179, then $129 quarterly, $119 for six months and $109 annually, with a $119 first month. Oral semaglutide: $179 against $209, then $159, $149 and $139, with a $149 first month. The GLP-1 and GIP line matches the injection at $149, $129, $119 and $109.
Branded vs compounded
Compounded semaglutide, injectable and oral, and a compounded GLP-1 and GIP product in the tirzepatide class, all marketed at reduced doses. Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, efficacy or quality before dispensing, and no published trial reports outcomes for a reduced protocol.
Pros and watch-outs
What we like
- The reduced-dose approach is stated rather than left to inference
- All four term lengths carry a published rate on every product
- The dual-agonist line is priced level with the semaglutide one
- $109 on an annual term is among the lower published figures
Watch-outs
- Three reductions on one headline obscure the standing rate
- The $119 first month reverts to $149 in month two
- A struck-through $179 compares against a price nobody pays
- No state list published
Best for
Buyers who have chosen a reduced-dose protocol and will read the terms.
Who should look elsewhere
Anyone wanting the titration the trials used, or one clear price.
How Lttl compares
A few alternatives worth a look, depending on what you’re optimizing for.
- SkinnyRx
A discounted rate, if it lasts
See SkinnyRx → - Bodybuilding Health+
A headline that is the month-to-month rate
See Bodybuilding Health+ → - Oak
Flat dose pricing without a subscription
See Oak →
More GLP-1 sellers by price reviews: AmbleApex MDAspenAuren RxBayan HealthBelle Health
Editor · Reviewed and last verified September 2026
How we assessed this. This review reflects GLP Loss’s own read of Lttl’s publicly-stated model — pricing transparency, clinical oversight, medication clarity, and access — against our editorial methodology. We publish no fabricated ratings or first-hand outcomes. A partnership never changes the assessment — see how we make money.
Frequently asked
- What does Lttl charge after the first month?
- $149 for the injectable semaglutide or the GLP-1 and GIP line, and $179 for the oral, unless a longer term was bought upfront. The $119 and $149 opening figures apply once. Month two is when the standing rate arrives.
- Is a low-dose program as effective as the trials?
- No trial answers that question. STEP 1 and SURMOUNT-1 both reported at full titrated doses, so a reduced protocol has no readout of its own. Prescribers do use lower doses deliberately for tolerability, and that is a legitimate approach — it is simply not the regimen behind the published numbers.
- What is the struck-through $179 doing?
- Presenting $149 as a reduction. Nothing on the page shows anyone paying $179, so the saving is measured against a reference rather than an alternative. The figures that decide a budget are $149 month to month and $109 on an annual term.
- Why does the oral cost more than the dual-agonist line?
- That is how the menu is built: $179 for oral semaglutide against $149 for the GLP-1 and GIP product. Sellers usually charge more for a tirzepatide-class drug than for any semaglutide. Here the tablet is the premium item instead.
- Is Lttl expensive compared with other GLP-1 sellers by price providers?
- Lttl publishes a starting figure of $149/mo. Across the 115 GLP-1 sellers by price providers we review that publish a single monthly figure, those run $76 to $369 with a median of $170, which puts Lttl below the median, toward the cheaper end. The other 5 GLP-1 sellers by price providers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.